Dermata Therapeutics Stock (NASDAQ: DRMA)

Dermata Therapeutics (NASDAQ:DRMA) Stock, Quote.Headers.trade-ideas

Dermata Therapeutics

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADGM

ALLR

APVO

AVGR

BBLG

CNEY

DRMA

GDHG

GLMD

HCWC

INTC

MYNA

NCPL

NKGN

OPTT

SMSI

SPRC

TNON

WHLR

ZVSA

Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Screenshot 2024-09-16 at 5.51.32 PM

Earnings

Equities

Eurozone

Commodities

IMMP

NCNA

NWTN

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September

ADAG

ATPC

EGIO

ENTO

IOBT

ITOS

LDTC

PPBT

PTIX

SQFT

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

Baird analyst Colin Sebastian maintains Corsair Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) with a Neutral and lowers the price target from $10 to $8.

Price Target

Analyst Ratings

CRSR

Baird Maintains Neutral on Corsair Gaming, Lowers Price Target to $8

Keybanc analyst Alex Markgraff maintains Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Overweight and lowers the price target from $145 to $135.

Keybanc Maintains Overweight on Global Payments, Lowers Price Target to $135

In October 2023, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">pipeline and cut costs</a>.
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
Sanofi&#8217;s consumer health unit boasts a portfolio that includes popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.&nbsp;
According to a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-24/sanofi-said-to-get-binding-bids-from-cd-r-pai-for-consumer-arm?srnd=prognosis&amp;embedded-checkout=true" rel="noreferrer noopener">report</a>, two private equity firms, Clayton Dubilier &amp; Rice and PAI Partners, made separate bids for Sanofi&#8217;s consumer health division.
The update pushes the European pharma giant closer to one of the largest European deals this year, which could value the unit at 15 billion euros ($16.8 billion) or more, the Bloomberg report added.
The separation is expected to occur by Q4 2024 by creating a publicly listed entity headquartered in France.
In July, Goldman Sachs Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and&nbsp;Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39755459/sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-6-5b-financing" rel="noreferrer noopener">Sanofi&#8217;s&nbsp;consumer health division</a>.
The move highlighted banks&#8217; interest in supporting leveraged buyouts through pre-arranged financing.
Sanofi may opt for a spinoff of its consumer health business if the offers aren&#8217;t appealing, Bloomberg noted, citing sources. A company spokesperson told Bloomberg that Sanofi is evaluating potential separation options, with the earliest possible transaction happening in the fourth quarter of this year, and noted that preparations are progressing as planned.
In November 2023, Sanofi reportedly initiated talks with Rothschild &amp; Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35823034/major-buyout-firms-eye-sanofis-consumer-health-division-spinoff-valued-over-20b" rel="noreferrer noopener">at over $20 billion</a>.&nbsp;
Rival pharma giants&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;and&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) split their consumer healthcare units&nbsp;Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Kenvue Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), respectively.
Price Action: SNY stock closed at $57.62&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/09/41012667/healthcare-software-giant-epic-systems-hit-with-lawsuit-over-alleged-monopolistic-practices" target="_blank" rel="noreferrer noopener">Healthcare Software Giant Epic Systems Hit With Lawsuit Over Alleged Monopolistic Practices</a>.</li>
</ul>
Photo via Company

Biotech

Large Cap

Health Care

Rumors

Media

General

KVUE

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff

Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/ACN/earnings">opening bell on Thursday, Sept. 26</a>.
Analysts expect the Dublin, Ireland-based company to report quarterly earnings at $2.78 per share, up from $2.71 per share in the year-ago period. Accenture projects to report revenue of $16.38 billion for the quarter, compared to $15.99 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 16, Accenture Federal Services won a $190M million U.S. Department of State Data and Systems Engineering contract.
Accenture shares gained 0.1% to close at $339.62 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f777c10bd99100018a435e/tien-tsin-huang">JP Morgan analyst Tien-Tsin Huang</a> maintained an Overweight rating and cut the price target from $376 to $370 on Sept. 24. This analyst has an accuracy rate of 61%.</li>
<li>Mizuho analyst Dan Doelev maintained an Outperform rating and boosted the price target from $352 to $365 on Sept. 18. This analyst has an accuracy rate of 63%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591ed97e290fa70001e6c69f/ashwin-shirvaikar">Citigroup analyst Ashwin Shirvaikar</a> maintained a Buy rating and raised the price target from $350 to $405 on Sept. 17. This analyst has an accuracy rate of 72%.</li>
<li>TD Cowen analyst Bryan Bergin maintained a Hold rating and raised the price target from $293 to $321 on Sept. 12. This analyst has an accuracy rate of 62%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5845b510ee7bf6000154d079/james-faucette">Morgan Stanley analyst James Faucette</a> downgraded the stock from Overweight to Equal-Weight rating and slashed the price target from $382 to $300 on June 26. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying ACN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="509" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-1024x509.png" alt="" class="wp-image-564748" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-1024x509.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-768x382.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192.png 1341w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41003853/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>

Accenture Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>ORKA-001 has an NHP half-life of 30.3 days following SQ administration and 33.8 days following IV administration, over three times longer than risankizumab and one of the longest NHP half-lives observed for an extended half-life antibody. Projections of ORKA-001 pharmacokinetics (PK) in humans indicate that a human half-life of approximately 50 days could enable dosing once every six months, while a human half-life of approximately 75 days could enable once-yearly dosing. The NHP half-life observed for ORKA-001 supports the potential to achieve these extended dosing intervals given that other YTE-modified antibodies have had an approximately two to four times longer half-life in humans than in NHPs. In addition, the extended half-life of ORKA-001 could result in higher antibody exposures than risankizumab, which could lead to greater efficacy. &nbsp;</li>
<li>ORKA-001 binds to a similar epitope with similar affinity to risankizumab and shows equivalent potency across a variety of in vitro assays. ORKA-001 binds IL-23p19 with an affinity below five picomolar. Based on cryo-EM structural analysis, ORKA-001 binds to a nearly identical epitope to risankizumab. When assessed across four different assays in cell lines and primary cells, ORKA-001 also had comparable functional potency for IL-23 antagonism. These findings support that ORKA-001 has a validated mechanism of action and further derisk its development path.</li>
</ul>

ORKA

Oruka Therapeutics Announced New Preclinical Data On ORKA-001, A Novel Extended Half-life Monoclonal Antibody Targeting IL-23p19, At The European Academy Of Dermatology And Venereology Congress

Emergent BioSolutions Announced It Has Secured Approximately $400M In Orders In 2024 And 2025 Associated With Its Vaccinia, Smallpox And Mpox Product Portfolio

JMP Securities analyst Aaron Hecht maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Market Outperform and raises the price target from $170 to $210.

JMP Securities Maintains Market Outperform on Lennar, Raises Price Target to $210

ABBV

AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 mg Or 30 mg) In Patients With Moderate-to-severe Atopic Dermatitis

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=18266891&amp;u=https%3A%2F%2Fwww.iridium.com%2F&amp;a=Iridium+Communications+Inc.">Iridium Communications Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), a leading provider of global voice and data satellite communications, today announced that the 3rd Generation Partnership Project (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=3188554480&amp;u=https%3A%2F%2Fwww.3gpp.org%2F&amp;a=3GPP">3GPP</a>) accepted Iridium's request to extend the functionality of Narrowband Internet of Things (NB-IoT) for Non-Terrestrial Networks (NTN) into the Work Plan for 3GPP Release 19 as an official Work Item. This will pave the way for Iridium's satellite service to be accessible via industry standard chipsets, furthering the company's progress in developing and deploying its newest service, Iridium NTN Direct℠, over the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=2436757427&amp;u=https%3A%2F%2Fwww.iridium.com%2Fnetwork%2F&amp;a=Iridium%C2%AE+Network">Iridium&#xAE; Network</a>. Born from the company's Project Stardust initiative, the Iridium NTN Direct service being announced today is expected to be the world's first truly global&nbsp;5G NB-IoT service. <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=945366429&amp;u=https%3A%2F%2Fwww.3gpp.org%2Fspecifications-technologies%2Freleases%2Frelease-19&amp;a=3GPP+Release+19">3GPP Release 19</a>&nbsp;is currently scheduled to be completed in the fourth quarter of 2025.
&nbsp;
In January 2024, Iridium announced <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=3667490169&amp;u=https%3A%2F%2Finvestor.iridium.com%2F2024-01-10-Iridium-Unveils-Project-Stardust-Developing-the-Only-Truly-Global%2C-Standards-Based-IoT-and-Direct-to-Device-Service&amp;a=Project+Stardust">Project Stardust</a> to enable NB-IoT NTN standards-based communication through its operational LEO constellation – and has since made considerable progress at a rapid pace. Iridium NTN Direct technical development is well underway, with a successful demonstration having taken place earlier this year in a lab environment. Iridium has also joined <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=36862901&amp;u=https%3A%2F%2Fwww.gsma.com%2F&amp;a=GSMA%2C">GSMA,</a> and is continuing to advance development with additional trials and demonstrations scheduled for early next year.
"We're already well into our technology development, and we're excited about our progress and to see so much enthusiasm from the 3GPP community," said Greg Pelton, CTO, Iridium. "As a cloud-based service powered by the flexibility of our software-defined satellites and building upon recognized industry standards, we've been able to jump off to a super-fast start. Our team is really motivated to make this happen."
Iridium NTN Direct will offer the opportunity for smartphone companies, OEMs, chipmakers, mobile network operators (MNO) and related IoT developers who utilize 3GPP standards-based technology to leverage Iridium's existing network and globally allocated and coordinated spectrum, providing a global, low-latency LEO user experience.
"When it comes to providing D2D, we don't have to be first, but we have to be the best. Iridium NTN Direct is an important initiative for us, and we've been able to pivot on an unprecedented scale and make significant progress toward providing the best service," said&nbsp;Matt Desch, CEO, Iridium. "We're grateful for the wide industry support of our vision to expand access to Iridium's global lifeline service by enabling it for anyone with a cellular device."
The Iridium satellite constellation's crosslinked, LEO architecture and global L-band spectrum provide a service advantage versus other LEO and geostationary satellite networks. Certified to provide safety of life services by international regulatory bodies, the Iridium network is known for its reliability and continues to be the only network that provides connectivity everywhere on Earth. Operating in LEO, the Iridium constellation does not suffer from the same line-of-sight limitations, significant power requirements or outages that can affect entire regions from a single satellite as faced by geostationary systems.

IRDM

Iridium's Satellite Service Gains Momentum for 2025 Global 5G NB-IoT Expansion

CLMB

Climb Channel Solutions, Wholly Owned Subsidiary Of Climb Global Solution Announced The Addition Of  A-LIGN, A Security Vendor Leading The Industry In Compliance, To Its Global Offerings

Greg Lucas has been promoted to the role of Vice President and Chief Accounting Officer, effective as of the same date.

Management

Thermon Group Names Jan L. Schott As Senior Vice President And CFO, Effective October 14, 2024

Macquarie analyst Paul Golding initiates coverage on Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Outperform rating and announces Price Target of $20.

Initiation

CLSK

Macquarie Initiates Coverage On Cleanspark with Outperform Rating, Announces Price Target of $20

Guidance

OCTO

Eightco Holdings Expects To Deliver Revenues Of $100M For 2025

Eightco Holdings Stated That It Has Made Significant Progress In 2024 By Improving Its Balance Sheet, Most Notably Through The Elimination Of $5.4M In Convertible Notes And Increasing Shareholder Equity By $23M

The scope of work includes constructing a new water treatment plant building, a storage facility, site improvements and demolition of the existing storage building and water treatment plant.
Southland was awarded this contract based on best value for this long-standing client. This award will be included in&nbsp;third quarter&nbsp;2024 backlog.

Contracts

SLND

Southland Holdings Secures $132M Contract To Construct New Water Treatment Plant For The Bureau Of Reclamation

KYMR

Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025

JMP Securities analyst Andrew Boone maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Market Outperform and raises the price target from $260 to $275.

DUOL

JMP Securities Maintains Market Outperform on Duolingo, Raises Price Target to $275

ALTR

Altair Announced Its Involvement In The £5.8M Performance Integrated Vehicle Optimization Technology Project, Supported By Innovate UK And The Advanced Propulsion Centre

Goldman Sachs analyst Brian Lee reiterates Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Buy and maintains $20 price target.

Reiteration

Goldman Sachs Reiterates Buy on Sunrun, Maintains $20 Price Target

STKH

Steakholder Foods Signed A Sales Agreement With Bondor Foods Ltd. to Supply Its Proprietary Plant-based Premixes For The Production Of A Line Of White Fish And Salmon Patties

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Dermata Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is taking off on Wednesday alongside heavy pre-market trading of the late-stage medical dermatology company&rsquo;s shares.



This has more than 13 million shares of DRMA stock changing hands as of this writing. That&rsquo;s well above its daily average trading volume of about 88,000 shares. Investors will also note that Dermata Therapeutics&rsquo; float is <a href="https://finance.yahoo.com/quote/DRMA/key-statistics/">only 433,330 shares</a>.



Investors will note that this movement comes without any news from Dermata Therapeutics today. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There also isn&rsquo;t any analyst coverage that would cause the shares to rally today.



What is worth keeping in mind is the fact that DRMA is a penny stock. This comes from its low daily average trading volume, its prior closing price of just $1.30 and its market capitalization of only $901,127.



<h2>What That means for DRMA Stock</h2>



Being a penny stock comes with certain disadvantages. That includes volatility. We&rsquo;ve seen some of this recently with shares of DRMA stock falling 22.6% during normal trading hours yesterday. That came with 1.4 million shares traded.



This also makes DRMA stock a risky investment. Traders will keep that in mind before taking a stake in the company.



DRMA stock is up 200% as of Wednesday morning.



Investors will want to keep reading for more of the most recent stock market news today!



We have all of the hottest stock market news traders need to know about on Wednesday! That includes the biggest pre-market stock movers this morning and more of the latest news. You can find all of this at the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/07/dear-sofi-stock-fans-mark-your-calendars-for-july-30-2/">Dear SOFI Stock Fans, Mark Your Calendars for July 30</a></li>



<li><a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">What Is Going on With Regencell Bioscience (RGC) Stock Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is falling hard on Wednesday morning after the biopharmaceutical&nbsp;company&rsquo;s shares underwent a massive rally yesterday.



Azitra stock is down 75.2% as of Wednesday morning. That comes with some 6.3 million shares of the stock traded. For the record, the company&rsquo;s daily average trading volume is <a href="https://finance.yahoo.com/quote/AZTR/">about 1.3 million shares</a>.



Yesterday&rsquo;s trading saw the tock close out normal hours up 206.8%. That came with more than 75 million shares of AZTR stock changing hands. Unfortunately for investors, today&rsquo;s drop erases the gains the company saw yesterday.



<h2>What Caused AZTR Stock to Rally?</h2>



Azitra&nbsp;shares surged higher in trading yesterday after the company <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">provided investors with patent updates</a>. That includes new ones and potential patents for its filaggrin-secreting strain of Staphylococcus epidermidis.



Azitra&rsquo;s patent update includes a few regions. Namely, the company has secured patents and options for future patents in the U.S., Canada and China. These cover using recombinant microorganisms to treat inflammatory skin disease and atopic dermatitis.



The wild movement AZTR stock has seen these last couple of days isn&rsquo;t unexpected. The company fits into the penny stock category with its pre-surge trading price of $1.62 cents per share and market capitalization of just $4.772 million. That means it&rsquo;s more susceptible to volatility.



Investors will want to keep reading for more of the most recent stock market stories today!



We have all of the hottest market happenings worth knowing about on Wednesday! A few examples include what&rsquo;s happening with shares of Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) and Dermata Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock, as well as the biggest pre-market stock movers today! All of that info is ready to go at the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">Why Is Nuzee (NUZE) Stock Up 133% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-down-75-today/">Why Is Azitra (AZTR) Stock Down 75% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Azitra (AZTR) Stock Down 75% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is heading higher on Wednesday alongside heavy pre-market trading of the coffee machine company&rsquo;s shares.



This has more than 8 million shares of NUZE stock changing hands as of this writing. That&rsquo;s well above its daily average trading volume of about 575,000 shares. Investors will also keep in mind that its <a href="https://finance.yahoo.com/quote/NUZE/key-statistics/">float is 560,520 shares</a>.



All of this activity comes without any clear news from Nuzee. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There also isn&rsquo;t any analyst coverage that would cause NUZE stock to rally today.



One thing investors will note is that NUZE is a penny stock. That comes from its prior closing price of $1.03 per share and its market capitalization of just $2.459 million.



<h2>Why That Matters to NUZE Stock</h2>



Being a penny stock comes with the risk of extra volatility. That makes sense as retail and day traders sometimes pump up these shares.



However, that also means the stock isn&rsquo;t likely to maintain its increased price. Once those traders sell their shares for profits, NUZE is likely to come back down from this high. Traders will want to weigh that potential when considering a stake in Nuzee.



NUZE stock is up 133% as of Wednesday morning.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news ready to go on Wednesday! Among that is what has shares of Dermata Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/07/dear-sofi-stock-fans-mark-your-calendars-for-july-30-2/">Dear SOFI Stock Fans, Mark Your Calendars for July 30</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">Why Is Nuzee (NUZE) Stock Up 133% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Nuzee (NUZE) Stock Up 133% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!



Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li>Cero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li>Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li>Signing Day Sports (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/">SGN</a>) shares are jumping more than 14% without any clear news this morning.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) stock is getting a 14% boost on Thursday morning.</li>



<li>Stellus Capital Investment (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li>Edwards Lifesciences (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/">EW</a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li>MaxLinear (NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/">MXL</a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is sliding more than 17% after a rally yesterday.</li>



<li>IF Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/">IROQ</a>) shares are falling over 16% despite a lack of news this morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

VSee Health, Dermata Therapeutics, and Exicure, Inc. are the 3 Penny Stocks to watch on August 6, based on&nbsp;TipRanks' Penny Stock Screener tool...

3 Penny Stocks to Watch Now, 8/6/24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) just reported results for the second quarter of 2024.<ul><li>Dermata Therapeutics reported earnings per share of -$4.18. This was below the analyst estimate for EPS of -$3.79.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/drma-stock-earnings-dermata-therapeutics-for-q2-of-2024/">DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024

Dermata Therapeutics GAAP EPS of -$4.18

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
What do you call a growth stock that isn&rsquo;t growing any more?



The answers are many. You can call it a disappointment. A drain on your portfolio. A bad investment. Any of these are true of F-rated <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a>, as evaluated by the Portfolio Grader.



And in today&rsquo;s market, you can ill-afford to a bad investment. The market is in some turmoil this summer.



I know it&rsquo;s only temporary, but times like these are when some investors start to panic and make bad decisions &ndash; particularly when they see their hard-earned money start to drain away in a sell-off.



It can be tempting to take a flyer on a stock in a weakened position. In fact, sometimes that can be a very good decision to buy strong growth stocks at a discount. 



You also need to be able to identify those opportunities rather than F-rated growth stocks that have little, if any, hope of bouncing back in the near future.



F-rated growth stocks are typically characterized by weak fundamentals, poor financial health, and inconsistent performance, which can lead to substantial losses. 



They can also be volatile, with extreme price fluctuations driven by speculation rather than solid financial performance.



We&rsquo;re using the Portfolio Grader today to help us identify the worst growth stocks available today, based on factors such as analyst sentiment, growth history, earnings reports and momentum. All of these names are on my list of stocks to avoid today.



<h2>Nio (NIO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/nio1600-2-300x169.png" alt="NIO logo, sign atop of North American headquarters and global software development center in Silicon Valley. NIO is Chinese electric autonomous vehicles manufacturer"><div>Source: Michael Vi / Shutterstock.com</div></div>Chinese EV maker&nbsp;Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>) has to be one of the most disappointing electric vehicle stocks. I had high hopes at one point that Nio&rsquo;s battery-swapping technology would be a difference-maker and would allow Nio to become a dominant EV company in Asia.



But not any longer. It&rsquo;s hard to have faith in any company that used to trade for $60 a share and now is down closer to $3.



Nio has had a lot of starts and stops. It&rsquo;s getting ready to launch its new mass market EV brand, Onvo, with the first Onvo model, the L60, to debut in September. 



There&rsquo;s also a lot of competition in the Chinese EV space, and Nio will likely be shut out by cars that are selling at a lower price point than the L60, which has a pre-order price of $30,460.



Nio reported delivering 20,498 vehicles in July, which is the third consecutive month that the company delivered more than 20,000 vehicles. But the market is obviously not impressed, as NIO stock is down 60% this year and 33% in the last three months.



Nio gets a &ldquo;D&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>FuelCell Energy (FCEL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/fcel1600-1-300x169.png" alt="Person holding cellphone with logo of US fuel cell company FuelCell Energy Inc. (FCEL) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>FuelCell Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/fcel-stock-quote/">FCEL</a>) manufactures, operates and services Direct Fuel Cell power plants that produce hydrogen. For providers who are looking for a green energy solution, hydrogen is appealing because it produces zero carbon emissions.



It has the potential to be highly efficient in fuel cells by providing more energy per unit of fuel compared to traditional combustion engines.



The company has more than 100 fuel cell plants in operation around the world and has generated more than 15.8 million megawatt-hours of power.



But just because it sounds like a good idea doesn&rsquo;t make something a good investment. Second-quarter revenue was $22.4 million, down from $38.3 million a year ago. FuelCell Energy posted a loss of $7.1 million, or 7 cents per share.



Obviously, growth is not in the cards for FuelCell, despite its efforts to expand its business in the Koren market. There are much better opportunities for investors.



FCEL stock is down 71% so far this year. It gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/muln1600-2-300x169.png" alt="In this photo illustration, the Mullen Technologies (MULN) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>Tell me if you&rsquo;ve heard this one before &ndash; Mullen Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/">MULN</a>) stock is below $1 per share again.



This is a sad repeat of a story that&rsquo;s plagued the EV company for the last several months. Mullen actually enacted three reverse stock splits last year, including a 1-for-100 split in December, in a desperate ploy to keep the stock price over $1 and maintain compliance with Nasdaq listing rules.



The cumulative ratio of all these stock splits are 1-for 22,500. And more dilution is on the way, as Mullen announced plans to resell up to <a href="https://www.sec.gov/Archives/edgar/data/1499961/000182912624005041/mullenautomotive_s1.htm#a_004">85 million shares</a> on the conversion of notes and exercise of warrants. 



When Mullen made the announcement there were only 24.85 million shares outstanding. Mullen acknowledged that the transactions could lead to &ldquo;substantial diminution to the value of shares of common stock held by our current stockholders.&rdquo;



Mullen only invoiced for 362 vehicles in six months ending March 31. It posted a net loss of $235 million in that period, while invoicing only $16.3 million.



Mullen stock is trying to make deals to turn things around, but another reverse stock split seems inevitable. MULN stock is down 95% this year and earns a &ldquo;C&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>SolarEdge Technologies (SEDG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/sedg-stock-1-300x169.jpg" alt="SolarEdge logo on phone with American flag background. SEDG stock"><div>Source: IgorGolovniov / Shutterstock.com</div></div>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) is another green power company. It makes power optimizers and inverters to help solar panels operate more efficiently.



The primary issue for SolarEdge, however, isn&rsquo;t the quality of its work or the efficiency of its equipment. It&rsquo;s the overall economy that makes solar power investment less appealing right now.



Interest rates remain inflated and the Fed seems stubbornly opposed to providing relief. Solar panels are a significant expense and fewer people are willing to borrow money to convert their homes to solar as long as interest rates remain high.



<a href="https://investors.solaredge.com/static-files/ab9d304f-bfed-4320-95b0-bc5bdee6d0b2">Revenue in the second quarter</a> was $265.4 million, down 73% from a year ago. The company posted a net loss of $130.8 million, a year after posting a profit of $119.5 million.



If interest rates drop, then SolarEdge may return to its growth ways. But that&rsquo;s not happening now. SEDG stock is down 75% this year and gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



<h2>2U (TWOU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/twou1600-300x169.png" alt="Person holding smartphone with logo of American educational technology company 2U Inc. on screen in front of web page. Focus on phone display. Unmodified photo. TWOU stock"><div>Source: T. Schneider / Shutterstock.com</div></div>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) is an educational technology company that works with nonprofit colleges and universities to create online degree and nondegree programs. But it hasn&rsquo;t been a great business model, as many colleges are able to offer online courses without outside help.



The Maryland-based company filed for Chapter 11 bankruptcy in July, after reporting more than $1 billion in debt in the first quarter and only $125 million in cash. 



2U announced a deal with&nbsp;<a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">lenders to cut its debt by 50%</a>, while extending the duration of its loan. It will also receive an additional $110 million in capital from lenders.



TWOU stock is down 95% this year and is approaching $1 per share despite instituting a 1-for-30 reverse stock split this summer. The stock is one to avoid.



TWOU gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



<h2>Dermata Therapeutics (DRMA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) is a clinical-stage biotechnology company based in California. Dermata is focused on creating treatments for skin conditions and diseases.



Its lead drug candidate, DMT310, is in Phase 3 trials for the treatment of acne, rosacea, and psoriasis. It is a once-weekly topical product made from naturally sourced freshwater sponges. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis.



The company says it&rsquo;s enrolled more than 50% of its patients in the trial and hopes to complete enrollment in the second half the year.



The challenge with biotech companies, of course, is that research and development is expensive and companies don&rsquo;t have a revenue stream during the long testing process. Companies are reliant on raising money and acquiring partners during the testing until they can bring a drug to market and start gaining revenue.



For the second quarter, Demata reported having $4.9 million in cash on hand, down from $7.4 million in the previous quarter. The company spent $4.8 million during the quarter on research and company operations, and raised $2.3 million from selling warrants.



The company believes it has sufficient funds to operate into the fourth quarter, so it will have to raise additional money if its going to continue its work.



DRMA stock is down 75% this year and gets a &ldquo;C&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Plug Power (PLUG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/plug1600-9-300x169.png" alt="Mobile phone with logo of American hydrogen fuel cell company Plug Power Inc. in front of business website. Focus on center of phone display. Unmodified photo. PLUG stock"><div>Source: T. Schneider / Shutterstock.com</div></div>Plug Power&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/plug-stock-quote/">PLUG</a>) had another bad day this week, as the company posted another disappointing earnings report that missed analysts&rsquo; expectations for both revenue and earnings per share.



The company, which is attempting to build the first commercially viable market for hydrogen fuel cell technology, posted revenue of $143.3 million for the second quarter, down from $260.1 million a year ago. 



The company also posted another <a href="https://www.ir.plugpower.com/press-releases/news-details/2024/Plug-Power-Announces-Key-Developments-and-Strategic-Milestones-in-Second-Quarter-2024/default.aspx">big operating loss</a> of $244.6 million slightly worse than the $233.8 million loss that Plug sustained in the second quarter of 2023. Overall, Plug&rsquo;s loss came in at 36 cents per share. 



Even though Plug has deployed more than 69,000 fuel cell systems and more than 250 fueling stations, I wouldn&rsquo;t call what its doing a viable business. At some point you need to start making money, and Plug isn&rsquo;t anywhere close.



Plug is projecting full-year revenue this year to be between $825 million and $925 million. A year ago it posted revenue of $891 million, so it appears growth this year will be challenging at best.



PLUG stock is down 54% this year and gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/08/7-f-rated-growth-stocks-to-avoid-like-the-plague-in-august-2024/">7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024

Dermata Therapeutics prices $3.5M equity offering

Dermata Therapeutics files to sell 5.87M shares of common stock for holders

AZTR

BLMZ

CERO

DRMAW

DTCK

FCEL

HOTH

INDV

IROQ

MULN

NUZE

PLUG

SEDG

SLNA

TIVC

TWOU

VKTX

VSEE

VSME

Press Releases

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Offerings

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Events

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Dermata Therapeutics

Dermata Therapeutics (DRMA) Forecast

Dermata Therapeutics (NASDAQ:DRMA) Stock, Quote.Headers.trade-ideas